Expert Review of Pharmacoeconomics & Outcomes Research

Taylor & Francis Online

ABDC C

Recent paperssorted by most recent

Paper	Year	Citations
Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands Lou M. Maas et al.	2026	1 citations
Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia Haarathi Chandriah et al.	2026	0 citations
Medication adherence research: expert perspectives on key HEOR trends for 2026 Tamás Ágh et al.	2026	0 citations
Cost-effectiveness analysis of point-of-care A1C tests in the primary care setting of Iran Abdoreza Mousavi et al.	2026	0 citations
Net benefits of investing in pulse oximetry and oxygen for childhood pneumonia in high burden countries Tim Colbourn & Carina King	2026	0 citations
Physicians’ preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China Yali Li et al.	2026	0 citations
Correction Unknown	2026	0 citations
Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer Mengmeng Liu et al.	2026	0 citations
Climate-related risk and pharmaceutical market dynamics in India and USA: evidence from transfer entropy, BEKK GARCH, and coherence wavelet Yedhu Harikumar et al.	2026	0 citations
Prevention, artificial intelligence, and mathematics in health economics: a framework for dynamic value modeling under long-term uncertainty Lieke Maas et al.	2026	0 citations
Duration changes and decision-making in DCE <sub>TTO</sub> : evidence from SF-6Dv2 Hosein Ameri & Thomas Gilbert Poder	2026	0 citations
Developing, updating and validating DepMod 2.0: an R-based decision-analytic model for the cost-effectiveness of depression interventions Stijn B. Peeters et al.	2026	0 citations
Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma Doris K Hansen et al.	2026	0 citations
Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033 Gittan Blezer et al.	2026	0 citations
Burden Tree – a conceptual framework for the burden associated with pediatric infectious diseases: a Delphi approach Cristina Carias et al.	2026	0 citations
Economic and humanistic burden of chronic liver diseases in the United States Javeria Khalid et al.	2026	0 citations
Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers’ submissions and a comparison between manufacturers and Canada’s Drug Agency (CDA) analyses Sepideh Mardani Jadid et al.	2026	0 citations
Cost consequence minimization and budget impact model for introducing the fully liquid combined acellular hexavalent vaccine into the Dominican Republic’s expanded immunization plan Rosa Acevedo Saladin et al.	2026	0 citations
Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation Rubén Queiro et al.	2026	0 citations
Impact of an expanded male catch-up HPV vaccination program on the clinical and economic burden of HPV-associated diseases in Denmark: a modeling study Emilie Theisen Honoré et al.	2026	0 citations

Search evidence from this journal →

Start a search

Access requires your institution's subscription. Ask your librarian →